Nectar Lifescience Ltd
Pharmaceuticals & Biotechnology | Small Cap
Nectar Lifescience Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strengths in solvency and profitability, driven by a solid equity base and returns on capital employed, alongside prudent capital expenditure management. However, it faces challenges in liquidity, growth, and efficiency, which are areas needing attention. The absence of revenue growth and low coverage ratios are significant concerns. While the company maintains a strong equity position, improvements in operational efficiency and revenue generation are crucial for sustained financial health and future prospects.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio2.00
- Financial Ratio4.00
- Profitability Ratio4.00
- Efficiency Ratio4.67
- Coverage Ratio2.00
- Solvency Ratio9.00
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
Nectar Lifescience Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strengths in solvency and profitability, driven by a solid equity base and returns on capital employed, alongside prudent capital expenditure management. However, it faces challenges in liquidity, growth, and efficiency, which are areas needing attention. The absence of revenue growth and low coverage ratios are significant concerns. While the company maintains a strong equity position, improvements in operational efficiency and revenue generation are crucial for sustained financial health and future prospects.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
-1.69
Industry Median
23.93
Small Cap Median
23.93
P/E RATIO
-2.67
P/B RATIO
0.32
Industry Median
2.53
Small Cap Median
2.53
P/S RATIO
0.18
Industry Median
1.35
Small Cap Median
1.35
Others
PEG RATIO
0.00
EV/EBITDA RATIO
-13.79
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹13.56 as on Jun 15, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Quarterly Report⬤23rd Jan 26
Quarterly Financial Results Q3 FY 2025-26
BEARISH SENTIMENT
The company's growth ratios are generally poor. The absence of revenue and net income growth, combined with negative growth in operating profit, earnings per share, and assets, indicates significant challenges in expanding its business. This suggests a need for strategic initiatives to stimulate growth and improve financial performance. Current trends pose a risk to future sustainability.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 8.05 | -8.71 | 10.66 | -1.07 | -99.88 |
| Operating Profit Growth Rate | 45.87 | -66.67 | 186.79 | -119.74 | 96.67 |
| Earnings Per Share (EPS) Growth | -134.25 | -196.43 | -120.37 | -2404.55 | 197.44 |
| Asset Growth Rate | 0.13 | -8.45 | 0.09 | -6.57 | -69.61 |
| Net Income Growth Rate | -134.25 | -196 | -120.83 | -2380 | 157.02 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios reveal a mixed performance. Capital expenditures are well-managed, but adjusted earnings per share, cash earnings per share, book value per share, and dividend per share are low. This suggests a need for improved earnings generation and shareholder returns. Efficient management of capital expenditures can support future growth, but enhancing overall financial performance is essential.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 0.82 | -2.95 | 0.23 | -5.18 | -3 |
| Cash Earnings Per Share (Cash EPS) | 3.73 | 1.59 | 3 | -2.36 | -15.42 |
| Book Value Per Share | 49.41 | 48.36 | 48.59 | 43.45 | 30.63 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 15 | 50 | 29 | 44 | 8 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability ratios present a mixed scenario. Returns on capital employed is good, but gross profit, return on equity, return on assets, operating margin, and net margin are low. This suggests limited overall profitability despite efficient capital utilization. Focus on improving margins and asset returns is crucial for enhancing overall profitability.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 6.13 | -0.39 | 5.41 | -5.53 | -2950 |
| Return on Capital Employed (ROCE) | 5 | 0 | 6 | -5 | -5 |
| Return on Equity (ROE) | 2.3 | -2.26 | 0.47 | -11.92 | -50.34 |
| Return on Assets (ROA) | 6.65 | 2.42 | 6.94 | -1.47 | -9.49 |
| Operating Margin | 9.55 | 3.49 | 9.04 | -1.8 | -2950 |
| Net Margin | 1.5 | -1.58 | 0.3 | -6.85 | -14650 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios present a mixed picture. While days sales in inventory and receivable days are high, fixed asset, inventory, receivables, and capital turnover ratios are very low. This suggests the company may not be effectively utilizing its assets to generate revenue, but has good sales days in inventory and good receivable days. Overall efficiency could be improved by optimizing asset utilization.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 2.3 | 2.3 | 2.62 | 2.63 | 0.02 |
| Inventory Turnover Ratio | 2.51 | 2.29 | 2.3 | 2.51 | 0.18 |
| Receivables Turnover Ratio | 4.05 | 4.18 | 5.1 | 4.6 | 0.01 |
| Days Sales in Inventory Ratio | 145.42 | 159.39 | 158.7 | 145.42 | 2027.78 |
| Receivable Days | 90.12 | 87.32 | 71.57 | 79.35 | 36500 |
| Capital Turnover Ratio | 1.21 | 1.18 | 1.39 | 1.64 | 0 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The coverage ratios are low, reflecting potential difficulties in meeting interest and dividend obligations. The interest coverage ratio, being close to the threshold, suggests a limited cushion for debt servicing. The equity dividend coverage ratio further confirms these challenges, highlighting the need for improved earnings and cash flow to comfortably cover these obligations.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 1.43 | 0.47 | 1.21 | -1.16 | -7.97 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's solvency position is strong. The absence of debt paired with a reasonably good equity ratio suggests financial stability and low risk of financial distress. This indicates a conservative approach to financing, which can be beneficial in volatile economic conditions. However, the company should ensure that this approach does not limit growth opportunities.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.21 | 0.18 | 0.12 | 0.06 | 0 |
| Debt to Equity Ratio | 0.27 | 0.22 | 0.14 | 0.06 | 0 |
| Equity Ratio | 0.79 | 0.82 | 0.88 | 0.94 | 1 |
| Debt To Asset Ratio | 0.12 | 0.1 | 0.06 | 0.03 | 0 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is weak. Low current, quick, and cash ratios indicate potential difficulties in meeting short-term obligations. The operating cash flow ratio further confirms these challenges, highlighting the need for improved working capital management to ensure smooth operational activities. This situation requires careful monitoring to avoid potential financial distress.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.56 | 1.61 | 1.51 | 1.32 | 12.92 |
| Quick Ratio | 0.91 | 0.86 | 0.79 | 0.65 | 12.92 |
| Cash Ratio | 0.02 | 0.02 | 0.02 | 0.02 | 2.87 |
| Operating Cash Flow Ratio | 0.09 | 0.15 | 0.23 | 0.16 | -8.95 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 2 | Kilitch Drugs (India) Ltd | 6.61 | 21.54 | Neutral | 37.00 | 9.27 | 30.00 |
| 3 | SMS Lifesciences India Ltd | 6.59 | 21.20 | Undervalued | 45.00 | 70.68 | 19.00 |
| 4 | Infinium Pharmachem Ltd | 6.42 | 26.90 | Neutral | 22.00 | 6.43 | 14.00 |
| 5 | Medicamen Biotech Ltd | 5.73 | 32.19 | Neutral | 20.00 | 6.94 | 10.00 |
| 6 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 59.71 | Neutral | 7.00 | 1.40 | 4.00 |
| 7 | Albert David Ltd | 5.63 | -272.47 | Neutral | 5.00 | -2.62 | -1.00 |
| 8 | BPL Ltd | 5.46 | -31.11 | Neutral | -4.82 | -3.00 | -8.55 |
| 9 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 10 | Lyka Labs Ltd | 4.77 | -23.98 | Neutral | -4.00 | -9.05 | -10.00 |
| 11 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
Nectar Lifescience Ltd's management effectiveness presents a mixed assessment. Strengths include sales growth and recent profit growth. However, concerns exist regarding Return on Equity (ROE), and promoter holding. The management's effectiveness is rated as mixed, reflecting both opportunities and challenges.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth | 3% (3Y) | Revenue expansion is evident. |
| Compounded Profit Growth | 28% (3Y) | Profit growth is recently strong. | |
| CONS | Return on Equity (ROE) | 0.47% | Shareholder funds yielding poor returns. |
| Promoter Holding | 44.53% (Mar 2025) | Decrease in promoter holding. |
Financial Performance & Growth
Nectar Lifescience Ltd has shown fluctuations in its financial performance. While sales have demonstrated some growth, particularly over the recent three-year period, profit growth has been inconsistent. There are fluctuations in quarterly sales and profits, indicating volatility in financial performance.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Sales Growth (%) | 15.7% | 18.3% | 0.9% | -8.7% | 10.7% | 0.1% |
| Operating Profit (₹ Cr) | 265 | 241 | 164 | 53 | 152 | 176 |
| Net Profit (₹ Cr) | 61 | 52 | -6 | -24 | 5 | 17 |
Capital Efficiency & Returns
The capital efficiency and returns of Nectar Lifescience Ltd show concerning trends. The Return on Capital Employed (ROCE) has been declining, indicating less effective use of capital. The Return on Equity (ROE) is very low, suggesting poor returns for shareholders. These metrics suggest that the company is not efficiently utilizing its capital to generate profits.
| Metric | 2013-2015 | 2016-2018 | 2019-2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| ROCE (%) | 12% | 10% | 7% | 5% | -0% | 6% |
| ROE (%) | NA | NA | NA | NA | NA | 0.47% |
Financial Health & Prudence
Nectar Lifescience Ltd's financial health and prudence reflect a situation with both strengths and weaknesses. The company has managed to reduce its borrowings over the years, which is a positive sign. However, the interest coverage ratio indicates that the company's ability to cover its interest expenses has fluctuated. The company has not been paying dividends.
| Metric | 2013-2015 | 2016-2018 | 2019-2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Borrowings (₹ Cr) | 904 | 932 | 862 | 860 | 754 | 636 |
| Interest Coverage Ratio | 2.31 | 2.07 | 0.96 | 2.01 | 0.67 | 1.75 |
| Dividend Payout (%) | 3.33 | 2.67 | 1.33 | 0 | 0 | 0 |
Shareholding & Ownership Structure
Nectar Lifescience Ltd's shareholding and ownership structure have undergone changes recently. There has been a decrease in promoter holding. FII holdings have fluctuated significantly, decreasing from 16.98% in March 2024 to 1.65% in March 2025. DII holding is very low. This shift in ownership could indicate changing investor sentiment or strategic decisions by the major stakeholders.
| Metric | 2017-Mar 2019 | 2020-Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Promoter Holding (%) | 55.80 | 55.80 | 55.80 | 55.80 | 44.53 |
| FII Holding (%) | 3.22 | 1.45 | 16.07 | 16.98 | 1.65 |
Nectar Lifescience Ltd faces a moderate risk profile due to segment performance volatility. The overall risk is assessed as moderate due to fluctuations in quarterly sales and profits.
Segment performance volatility
Nectar Lifescience Ltd demonstrates segment performance volatility, as evidenced by fluctuations in quarterly sales and profits. The company must proactively manage its diverse segments to ensure consistent overall financial health.
| Quarter | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales (₹ Cr) | 443.01 | 476.24 | 403.03 | 388.65 | 344.13 | 388.81 | 394.13 | 397.97 | 452.17 | 441.38 | 359.30 | 428.09 | 454.98 |
| Net Profit (₹ Cr) | 9.73 | 11.66 | 3.90 | -22.47 | -9.29 | 3.68 | 1.82 | 1.02 | 1.57 | 0.59 | 2.97 | 5.60 | 7.84 |
Foreign exchange or interest rate exposure
Nectar Lifescience Ltd is exposed to foreign exchange or interest rate risks due to its operations. Changes in interest rates can affect borrowing costs and financial performance. The company's financial performance could be influenced by these external factors.
| Year | 2013 | 2016 | 2019 | 2022 | 2024 |
|---|---|---|---|---|---|
| Interest Paid (₹ Cr) | 115 | 123 | 148 | 79 | 87 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe